Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPL-003 in Treatment-Resistant Depression
NCT05870540Phase 2Completed
- Sponsor
- Beckley Psytech
- Start
- Sep 2023
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 2, randomised, triple-blind trial of mebufotenin in treatment-resistant depression (TRD) (5 arms), sponsored by Beckley Psytech. Primary endpoints: Montgomery and Asberg Depression Rating Scale Total Score at 4 weeks and Treatment-emergent Adverse Events at 8 weeks. Started Sep 2023; status: completed.
02
Drugs
mebufotenin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT05870540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870540.